Status:
COMPLETED
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Congenital Adrenal Hyperplasia
Eligibility:
All Genders
18+ years
Brief Summary
Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in particular the chronic (over-...
Detailed Description
Treatment with glucocorticoids and mineralocorticoids has changed congenital adrenal hyperplasia (CAH) from a fatal to a chronic lifelong disease. Long-term treatment, in particular the chronic (over-...
Eligibility Criteria
Inclusion
- Inclusion criteria : patients
- Patients \> 18 yrs with classical or non classical CAH diagnosed during childhood
- Absence of known cardiovascular disease
- Absence of combined oral contraceptives during the previous month
- Inclusion criteria : controls
- Age \> 18 yrs
- Absence of known cardiovascular disease
- Absence of combined oral contraceptives during the previous month
- Exclusion criteria :
- Blood donation during the previous 3 months
- Cardiovascular disease
- Treatment by combined oral contraceptives
- Pregnancy
Exclusion
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT01807364
Start Date
May 1 2011
End Date
April 1 2016
Last Update
June 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié Salpêtrière Hospital
Paris, France, 75013